Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actelion and Nippon Shinyaku have signed a license agreement on a novel orally available PGI2 receptor agonist NS-304 originally discovered and synthesized by Nippon Shinyaku for the treatment of pulmonary arterial hypertension.
Subscribe to our email newsletter
Under the terms of this license agreement, Nippon Shinyaku will receive from Actelion an upfront payment and additional milestone payments based on development stage and sales achievement. Nippon Shinyaku will also receive royalties on sales. In addition, this agreement enables Nippon Shinyaku to explore the possibility of co-development in Japan of a compound which is being developed by Actelion globally.
In order to promptly bring NS-304 to the market of pulmonary arterial hypertension and other possible indications, Actelion will take over the Phase IIa clinical study being conducted by Nippon Shinyaku in Europe and be responsible for global development and commercialization of NS-304 outside Japan. The two companies will co-develop and co-commercialize NS-304 in Japan.